TGFB1 and neoplasm: Not only TGF-β expression was decreased, but fewer TGF-β I receptors on cell surfaces were found after sorafenib treatment (Figure 2C), suggesting that sorafenib blocks the TGF-β signaling pathway, which is critical for tumor progression and immunosuppression.